Author + information
- Do-Yoon Kang,
- Cheol Hyun Lee,
- Osung Kwon,
- Kyusup Lee,
- Pil Hyung Lee,
- Jung-Min Ahn,
- Duk-Woo Park,
- Soo-Jin Kang,
- Seung-Whan Lee,
- Young-Hak Kim,
- Cheol Whan Lee,
- Seong-Wook Park and
- Seung-Jung Park
More flexible and highly deliverable Resolute Integrity Zotarolimus-eluting stents (R-ZES) have been developed and used to treat very complex coronary lesion anatomies. This study evaluated the safety and efficacy of R-ZES in the treatment of unprotected left main coronary artery (ULMCA) stenosis.
The PRECOMBAT-4 study prospectively enrolled 313 consecutive patients receiving R-ZES for ULMCA stenosis. We compared these patients with those received Promus Element platinum chromium everolimus-eluting stents (PtCr-EES) (n=295) in the PRECOMBAT 3 trial. The primary endpoint was the major adverse cardiac or cerebrovascular events (MACCE), including death, myocardial infarction, stroke, or target vessel revascularization at 3 years.
MACCE occurred in 45 patients (28 deaths from any cause, 5 myocardial infarctions, 3 strokes, and 15 target vessel revascularizations). The incidence of MACCE in patients with R-ZES (14.3%) was similar with PtCr-EES (14.9%, adjusted hazard ratio [aHR], 0.92; 95% confidence interval [CI], 0.58-1.45; P = 0.73). R-ZES also showed a comparable risk of the composite incidence of death, MI, or stroke (aHR, 1.07; 95% CI, 0.61-1.88; P = 0.82), and target vessel revascularization (aHR, 0.82; 95% CI, 0.39-1.74; P = 0.61) with PtCr-EES.
R-ZES showed comparable safety and effective strategy with PtCr-EES in the treatment of ULMCA stenosis.
Poster Hall, Hall A/B
Saturday, March 10, 2018, 10:00 a.m.-10:45 a.m.
Session Title: Interventional Cardiology: Coronary Interventions of Complex Lesions, Left Main Disease, BVS and Advanced Imagery
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1114-256
- 2018 American College of Cardiology Foundation